Adaptimmune therapeutics plc (ADAP)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Cash flows from operating activities
Net loss

-28,167

-29,364

-39,302

-41,087

-27,412

-36,173

5,242

-43,505

-21,078

-27,263

-878

-20,215

-21,782

-15,414

-18,494

-22,095

-15,576

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation

1,711

1,766

1,764

1,814

1,828

1,940

1,749

1,759

1,740

1,614

1,395

1,037

986

836

778

805

707

Amortization

180

327

178

166

167

158

160

161

143

124

108

99

60

38

40

44

38

Share-based compensation expense

1,448

2,558

1,820

3,196

3,479

3,749

4,042

3,739

4,672

2,848

3,199

2,071

2,686

1,996

2,284

2,467

2,074

Realized loss on available-for-sale debt securities

-

-

-

-

-

0

0

1,310

1,163

-

-

-

-

-

-

-

-

Unrealized foreign exchange gains

1,745

-554

526

-6,143

5,095

-4,826

-2,006

-10,777

7,862

1,713

3,680

3,154

52

-629

-61

396

1,608

Other

145

10

-42

-114

-39

-25

246

-108

124

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Increase in receivables and other operating assets

3,193

-18,639

3,224

10,192

6,659

1,022

-7,462

1,423

10,179

11,526

-1,879

-4,114

1,813

5,621

1,513

-1,090

489

Increase in non-current operating assets

259

2,918

-205

-1,282

19

-252

-403

-210

123

-2,599

-70

537

17

-180

0

-206

-1,835

Decrease in payables

-2,708

-

-

-

-2,453

-

-

-

-

-

-

-

-

-

-

-

-

Increase in deferred revenue

49,445

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Increase (decrease) in payables and deferred revenue

-

-

-

-

-

-5,390

-11,371

-8,283

-15,879

11,580

10,984

-1,618

-8,507

19,604

1,478

1,386

-5,660

Net cash provided by (used in) operating activities

16,857

-12,521

-29,608

-34,168

-36,203

-31,685

9,939

-35,363

-47,279

-21,356

13,489

-18,009

-28,439

2,370

-15,366

-16,493

-18,679

Acquisition of property, plant and equipment

192

167

223

298

904

87

684

1,235

1,904

1,852

1,603

8,939

12,249

6,666

1,930

1,202

1,708

Acquisition of intangibles

152

446

114

717

205

132

656

0

10

81

22

24

242

255

163

0

861

Maturity of short-term deposits

-

-

-

-

-

-

-

-

-

-20

17,788

15,003

7,854

23,880

7,836

33,668

7,993

Investment in short-term deposits

-

-

-

-

-

-

-

-

-

0

0

0

18,000

0

0

26,849

15,988

Maturity or redemption of marketable securities

26,364

32,500

38,479

31,655

22,669

23,050

44,271

42,674

28,043

-

-

-

-

-

-

-

-

Investment in marketable securities

97,967

8,204

3,097

12,079

3,904

75,242

41,989

21,066

12,490

-

-

-

-

-

-

-

-

Net cash (used in) provided by investing activities

-71,947

23,683

35,045

18,561

17,656

-52,411

942

20,373

13,639

-40,011

9,751

-73,184

-22,637

16,959

5,743

5,617

-10,564

Cash flows from financing activities
Proceeds from issuance of common stock, net of issuance costs of $979 and $nil

90,550

-

-

-

-

-

-

-

-

0

0

41,770

61,397

-

-

-

-

Proceeds from exercise of stock options

894

0

0

330

36

104

509

890

1,534

-

-

-

-

-

-

-

-

Net cash provided by financing activities

91,444

0

0

330

36

104

100,162

890

1,534

0

370

41,801

61,397

-

-

-

-

Effect of currency exchange rate changes on cash, cash equivalents and restricted cash

-502

26

-687

-136

425

-776

-306

2,872

1,545

105

-206

938

1,491

-

-

-

-1,349

Net increase (decrease) in cash and cash equivalents

35,852

11,181

4,750

-15,413

-18,086

-84,768

110,737

-11,228

-30,561

-61,262

23,404

-48,454

11,812

17,848

-10,175

-13,056

-30,592